Product news

Share this article:
Nycomed said the FDA has approved Alvesco (ciclesonide) inhalation aerosol in the US for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older. Alvesco is an inhaled corticosteroid with novel release and distribution properties.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.